Physiological Impact of Abnormal Lipoxin A<sub>4</sub> Production on Cystic Fibrosis Airway Epithelium and Therapeutic Potential

Gerard Higgins,<sup>1,2</sup> Fiona Ringholz,<sup>1,2</sup> Paul Buchanan,<sup>1</sup> Paul McNally,<sup>1</sup> and Valérie Urbach<sup>1,2,3</sup>

<sup>1</sup>National Children's Research Centre, Crumlin, Dublin 12, Ireland
<sup>2</sup>Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin 9, Ireland
<sup>3</sup>Institut National de la Santé et de la Recherche Médicale, U845, Faculté de Médecine Paris Descartes, Site Necker, 156 rue Vaugirard, 75015 Paris, France

Correspondence should be addressed to Valérie Urbach; valerie.urbach@gmail.com

Received 20 June 2014; Revised 22 September 2014; Accepted 23 September 2014

Academic Editor: Carlos Artério Sorgi

Copyright © 2015 Gerard Higgins et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Lipoxin A<sub>4</sub> has been described as a major signal for the resolution of inflammation and is abnormally produced in the lungs of patients with cystic fibrosis (CF). In CF, the loss of chloride transport caused by the mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) Cl<sup>-</sup> channel gene results in dehydration, mucus plugging, and reduction of the airway surface liquid layer (ASL) height which favour chronic lung infection and neutrophil based inflammation leading to progressive lung destruction and early death of people with CF. This review highlights the unique ability of LXA<sub>4</sub> to restore airway surface hydration, to stimulate airway epithelial repair, and to antagonise the proinflammatory program of the CF airway, circumventing some of the most difficult aspects of CF pathophysiology. The report points out novel aspects of the cellular mechanism involved in the physiological response to LXA<sub>4</sub>, including release of ATP from airway epithelial cell via pannexin channel and subsequent activation of P2Y<sub>11</sub> purinoreceptor. Therefore, inadequate endogenous LXA<sub>4</sub> biosynthesis reported in CF exacerbates the ion transport abnormality and defective mucociliary clearance, in addition to impairing the resolution of inflammation, thus amplifying the vicious circle of airway dehydration, chronic infection, and inflammation.

1. Lipoxin A<sub>4</sub>

1.1. Lipoxin A<sub>4</sub> and Eicosanoid Class Switching. Lipoxin A<sub>4</sub> (LXA<sub>4</sub>) belongs to a class of newly identified specialised proresolution lipid mediators playing a central role in the resolution of inflammation which results from the sequential production of characteristic eicosanoids in a process termed “class switching” [1, 2]. Prostaglandins are biosynthesized early, initiating the acute inflammatory response. Then Leukotrienes typified by Leukotriene B<sub>4</sub> (LTB<sub>4</sub>) play a role in the amplification and propagation of inflammation [1] acting in concert with the peptide Interleukin 8 (IL8) as a potent neutrophil chemoattractant [3, 4]. Both LTB<sub>4</sub> and IL8 are negatively correlated with pulmonary function in CF. LXA<sub>4</sub> is the first eicosanoid expressed in the active resolution phase of inflammation [5] followed by biosynthesis of the Resolvins and Protectins. LTB<sub>4</sub> and LXA<sub>4</sub> are closely related metabolites of arachidonic acid and can be synthesised from a common unstable intermediate [3].

1.2. Lipoxin A<sub>4</sub> Synthesis. LXA<sub>4</sub> is produced by multistep enzymatic process resulting from lipooxygenase (LO) activities in different cell types [6]. Neutrophils [7], eosinophils [8], alveolar macrophages [9], platelets [10], or airway epithelial cells [11] express different LO which act in sequence in LXA<sub>4</sub> biosynthesis [3, 12].

Two main pathways will result in LXA<sub>4</sub> synthesis. One involves lipooxygenation of arachidonic acid by 15-LO in macrophages and epithelial cells. The 5-LO expressed by neutrophils can then utilise the 15(S)-hydroxyeicosatetraenoic acid (15S-HETE) released as a substrate to synthesize LXA<sub>4</sub> [7] (Figure 1, blue arrows). Alternatively, platelet 12-LO [10] and macrophage or epithelial 15-LO [13, 14] are each able to transform Leukotriene A<sub>4</sub>, released by neutrophils, into
**Neutrophils**

![Diagram of lipoxin A₄ (LXA₄) biosynthesis](image)

**Airway epithelial cells**

**5-LO**

AA → **LTA₄**

**LXA₄**

**15-LO**

**15S-HETE**

**LXA₄** (Figure 1, brown arrows). The activity of 15-LO promotes LXA₄ biosynthesis and blocks leukotriene biosynthesis, both as a result of 15-LO products competing for flux at the 5-LO level and by diversion of the intermediate Leukotriene A₄ away from LTB₄ towards LXA₄ biosynthesis [1, 11, 15].

LXA₄ (Figure 1, brown arrows). The activity of 15-LO promotes LXA₄ biosynthesis and blocks leukotriene biosynthesis, both as a result of 15-LO products competing for flux at the 5-LO level and by diversion of the intermediate Leukotriene A₄ away from LTB₄ towards LXA₄ biosynthesis [1, 11, 15].

1.3. Lipoxin A₄ Anti-Inflammatory Actions. The anti-inflammatory action of LXA₄ is mainly mediated by the formylpeptide receptor 2 (FPR2) which is one member of a subgroup of receptors linked to inhibitory G-proteins, also called ALX [16, 17]. FPR2 receptor activation by specific agonists results in transient Ca²⁺ flux, phosphorylation of extracellular signal regulated kinases (ERK), and chemotaxis [18]. The molecular and pharmacological characterization of FPR2 receptor have been previously reviewed [19, 20]. Briefly, the seventh transmembrane domain of the FPR2 receptor is essential for LXA₄ recognition, whereas the additional regions of the receptor (e.g., extracellular loops) are required for high affinity binding of the peptide ligands [17, 19, 20]. LXA₄ also interacts directly with the cysteinyl receptor to transduce signals that prevent the proinflammatory response and contributes to the active resolution of inflammation [18, 21].

LXA₄ inhibits neutrophil effector functions [5] and in particular inhibits LTB₄ induced neutrophil transmigration [22–24]. LXA₄ suppresses IL8 production by leukocytes and bronchial epithelial cells including airway epithelial cells from patients with cystic fibrosis [25–28]. Mice treated with analogues of LXA₄ and subsequently challenged with *P. aeruginosa* contained the bacterial challenge more effectively [29]. LXA₄ affects leukocytes in a cell type specific manner, inhibiting the activation of polymorphonuclears (PMNs) and eosinophils whilst activating monocytes and macrophages. PMN recruitment is a multistep process that involves chemotaxis, adhesion, and transmigration. In *in vitro* models LXA₄, LXB₄, and ATLS inhibit PMN chemotaxis in response to the chemoattractant LTB₄ and inhibit eosinophil responses to platelet activating factor. Stimulation of macrophages with LXA₄ significantly enhances phagocytosis of apoptotic PMNs, suggesting that LXA₄ can promote the clearance of apoptotic leukocytes by macrophages at an inflammatory site [30, 31].

2. Cystic Fibrosis

2.1. Cystic Fibrosis Disease and the CF Gene. Cystic fibrosis (CF) is the most common lethal genetic disorder in Caucasians caused by a mutation in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR). The disease was first characterised in 1938 by Andersen who described the cystic fibrosis of the pancreas and correlated it with the lung and intestinal disease that occurs in CF [32]. In 1953, the observation of excessive salt loss in the sweat of CF patients was noted; however, it was not until 1983 that it was first shown that sufferers of CF displayed abnormal chloride transport. This discovery was not sufficient for the identification of the defective protein in CF patients. In 1985 polymorphic markers associated with the disease were identified and finally the CFTR gene was identified [33–35].

The CFTR protein is principally expressed in the apical membranes of epithelia where it acts as an anion channel providing a pathway for Cl⁻ and bicarbonate (HCO₃⁻) movement, controlling the rate of fluid flow, and also regulating the function of other ion channels and transporters in epithelial cells [36, 37]. A number of different CFTR mutations have been identified that lead to differing outcomes in terms of protein synthesis, trafficking, regulation, and CFTR levels within the cell [38, 39]. CFTR is abundantly expressed in epithelial cell membranes and, as such, CF disease particularly affects epithelial sites: the submucosal glands, airway surface epithelium [40], pancreatic ductal epithelium, the epithelium of the crypts of Lieberkuhn throughout the gastrointestinal tract [41], the epithelium of sweat glands [42], the epithelium of the developing genital ducts, adult epididymis and vas deferens, and the cervical and the uterine epithelial surfaces [43, 44]. However, there are exceptions among epithelial tissues where CF related dysfunction is not prominent, such as kidney collecting ducts, the epithelium of Burners gland, and the submucosal glands of the duodenum [44]. The major clinical features of CF are chronic pulmonary disease, exocrine pancreatic insufficiency, and male infertility. CF lung disease reflects the failure of airflow defence against chronic bacterial infection, leading to an aggravated immune response, bronchial epithelial remodelling, and ultimately lung destruction. The progressive lung destruction is the main cause of morbidity and mortality in CF [45, 46]. Whilst it was initially believed that the pulmonary...
complaints associated with CF were directly related to the CFTR dysfunction in epithelial cells, it is now recognised that other cell types including neutrophils [47, 48], macrophages [49, 50], and dendritic cells [51] are directly affected by the absence or dysfunctional CFTR.

2.2. Abnormal Production of Lipoxin A₄ in Cystic Fibrosis. In addition to CFTR dysfunction, other abnormalities have been described in chronically inflamed and infected CF airways, including intrinsic proinflammatory properties, amplified inflammatory responses to infections, and reduced bacterial clearance. More specifically, the levels of LXA₄ have been reported to be decreased in CF, like in other chronic airway inflammatory diseases such as asthma [29, 52–55]. A significant suppression in LXA₄/neutrophil ratios in bronchoalveolar lavages (BAL) fluid of patients with CF compared with pulmonary inflammatory controls was reported [29, 56]. Furthermore, in pediatric CF BAL even in the absence of infection, the ratio of LXA₄ to LTB₄ is depressed and this correlates with a significant lower level of 15 LO-2 transcripts in CF BAL [2]. A decreased proportion of proresolving compounds (LXA₄) compared to proinflammatory (LTB₄) is associated with decreased lung function parameters [57]. In addition, in vitro studies support a role for CFTR in LXA₄ production. The inhibition of CFTR reduces LXA₄ synthesis by 50% during platelets/PMN coculture by inhibiting the lipoxin synthase activity of platelets 12-LO. This correlated with the observation that platelets from patients with CF generated 40% less LXA₄ compared to healthy subjects [58]. The decreased LXA₄ production in CF provides a mechanistic explanation of the failure to actively resolve acute airway inflammation seen in these patients.

3. Regulation of Ion Transport and Airway Surface Liquid Layer in Cystic Fibrosis

3.1. Abnormal Ion and Fluid Transport in Cystic Fibrosis. The lung must continually defend itself against bacteria that deposit on the airway surfaces during normal tidal breathing. Mucus clearance is a primary form of pulmonary defence and the efficiency of mucociliary clearance in large part depends upon the volume of the airway surface liquid layer (ASL). The ASL allows for mucus containing foreign bodies to be transported away from the lung to the oropharynx where it is either expelled from the body or swallowed and destroyed by the gut. The ASL provides a low viscosity solution allowing free ciliary beat and mucus transport [59]. The normal hydration of the airway surface is maintained (in the highly water permeable airway epithelium) by active ion-transport controlling the quantity of salt (NaCl) delivered to airway surfaces, with water following passively by osmosis [60]. The NaCl concentration of the airway surface liquid is tightly regulated in normal airway epithelia by the epithelial sodium channel (ENaC) mediated Na⁺ absorption and Cl⁻ secretion. Cl⁻ is secreted by epithelial cells via the apical CFTR Cl⁻ channel and calcium activated Cl⁻ channels, with Cl⁻ entering the cell through the Na⁺–K⁺–2Cl⁻ cotransporter located in the basolateral membrane. Regulation of Cl⁻ secretion determines the net transport of ions across the epithelium and hence the mass of salt on the epithelial surfaces. CFTR was also found to regulate ENaC suggesting that CFTR acted both as a Cl⁻ channel and as a regulator of other ion transport processes. In CF, mutations of the CFTR gene result in defective Cl⁻ secretion and Na⁺ hyperabsorption by airway epithelia [61, 62]. Studies in CF airway epithelium cultures, transgenic mice, and people with CF suggest that the initiating event in CF airway disease is a reduced ASL volume resulting from dehydration. This dehydration leads to reduced mucus clearance, adhesion of mucus to airway surfaces, and chronic bacterial infection of the lung (Figure 2). The chronic bacterial infection leads to an aggravated immune response, bronchial epithelial remodelling, and ultimately lung destruction [59, 63–70].

3.2. Lipoxin A₄ Restores Fluid Transport in Cystic Fibrosis. One of the greatest challenges of fundamental research into reversing the CF defect in the lung has been to design a strategy to overcome the absence of functional CFTR by stimulating chloride secretion via alternative pathways, thus restoring airway hydration and mucociliary clearance. This can be achieved via the stimulation of calcium activated Cl⁻ agents that raise the intracellular concentration of calcium. Yet, this strategy has been plagued by the side effects of the amplification of the calcium-dependent proinflammatory response resulting in undesirable activation of NFκB. In addition to its anti-inflammatory properties, LXA₄ stimulates a rapid and transient intracellular Ca²⁺ increase in normal and CF bronchial epithelial cells expressing the FPR2 receptor [71, 72]. This intracellular calcium signal is mainly due to calcium mobilisation from intracellular calcium stores in non-CF airway epithelial cells and due to calcium entry and intracellular calcium release in CF airway epithelial cells. In both, non-CF and CF bronchial epithelia, LXA₄ stimulates whole-cell Cl⁻ currents which are inhibited by NPPB (calcium-activated Cl⁻ channel inhibitor) and BAPTA-AM (chelator of intracellular Ca²⁺) but not by CFTrih-172 (CFTR inhibitor) [71, 72]. Furthermore, in models of fully differentiated bronchial epithelia derived from primary culture of bronchial brushings from patients with CF and cultured under air-liquid interface, LXA₄’s effects on ion transport result in an increase of the airway surface liquid (ASL) layer height. LXA₄ exerts this effect on the ASL dynamics via the FPR2 receptor. The sustained increase in ASL height induced by LXA₄ in non-CF and CF bronchial epithelia results from inhibition of amiloride-sensitive Na⁺ absorption and stimulation of an intracellular calcium signal and Ca²⁺-activated Cl⁻ secretion independent from CFTR [72, 73]. LXA₄ thus restores Cl⁻ secretion and normal ASL height both central to the pathophysiology of CF airway disease, highlighting a role for LXA₄ in the restoration of normal innate immune defence (Figure 2).

4. Nucleotides and CF Airway Disease

4.1. Regulation of ASL and Mucociliary Clearance by Nucleotides. Mason et al. first proposed that extracellular ATP regulates ion transport rates when added to either the apical
or basolateral surface of human airway epithelium and found that these effects appear to be mediated by cell surface receptors that respond to ATP by regulating ion transport rates through the release of Ca^{2+} from internal stores and extracellular Ca^{2+} influx [74]. As agonists were being screened to restore Cl− and fluid secretion in CF airway epithelium, nucleotide agonists emerged quickly as stimulants of Cl− and fluid secretion independent of CFTR. Knowles et al. showed that extracellular nucleotides stimulated Cl− secretion in CF patients. Purinergic agonists in addition to ATP such as UTP, UDP, and ADP also had the power to stimulate Cl− secretion in CF and non-CF airway epithelial models [75]. In addition, adenosine receptors can also stimulate Cl− secretion in airway epithelial cells by activating the cAMP/PKA signal transduction pathway and eventually CFTR. ATP signalling through purinergic P2Y receptors is effective in airway epithelia in inhibiting ENaC activity and initiating Ca^{2+}-activated Cl− secretion [78]. All functionally defined P2Y receptors are able to couple through the IP_3 pathway consisting of activation of PLC increase in inositol phosphates and mobilization of Ca^{2+} from intracellular stores. In addition and secondary to the activation of the PLC, multiple signal transduction pathways including PKC, phospholipase A_2, Ca^{2+} sensitive ion channels, and formation of endothelium derived relaxing factors have been shown to be involved in the responses to activation of native P2Y-receptors. Another function of the P2Y receptors is the activation of ciliary beat frequency. In hydrated airways, the rate of mucociliary clearance is determined by ciliary beat frequency and nonsaturating concentrations of ATP generate alternating Ca^{2+} signals in ciliated cells which in turn increases ciliary beat frequency [79, 80].

Pharmacological data has shown that the P2Y11 receptor is preferentially activated by ATP and is uniquely coupled to both the phosphoinositide and the cAMP pathways [81]. Evidence is available that ATP and ADP, two physiologic nucleotides that can be released into the extracellular space, are able to raise cAMP levels in native cells via activation of P2Y11 receptors. Those results provide a mechanism in addition to activation of P2Y2 or adenosine receptors, by which exogenous or endogenously related nucleotides can increase cellular levels of this important cyclic nucleotide. Given the evidence that a number of types of cells both release ATP and possess P2Y11 receptor, then nucleotide mediated activation of P2Y11 receptors provides a means for autocrine regulation of epithelial and other cell types. Activation of the P2Y11 receptor in different cell types has a number of different outcomes. For example, the P2Y11 receptor mediates the inhibition of neutrophil apoptosis, impaired endothelial cell proliferation or regulation of secretory function of pancreatic ductal cells by ATP [82–84].

4.2. Nucleotides Release by Pannexin Channel. The complex cellular composition of the airways that is ciliated cells and mucin-secretory goblet cells suggests that several mechanisms and pathways are involved in the release of nucleotides into the airways. Two general mechanisms for the release of ATP from cells have been proposed as vesicular release and channel-mediated release. While vesicular release of ATP is well documented, ATP release can also occur in the absence of vesicles. For example, human erythrocyte which is devoid of cytoplasmic vesicle can release ATP in low oxygen content or in response to shear stress [85]. Pannexins belong to the family of connexin channels that have been proposed as diffusion pathways for ATP release under various experimental conditions. The Pannexins primarily form oligomeric structures embedded in a single plasma membrane that when open provide a conduction pathway between cytosol and extracellular space. They are mechanosensitive and are highly permeable to ATP [86]. Exposure of the alveolar A549 cells to

![Figure 2](image-url)
Figure 3: Lipoxin A₄ enhances epithelial barrier integrity by stimulating an increase in airway surface liquid (ASL) layer height, epithelial repair, and tight junction formation. Stimulation of the FPR2 receptor by LXA₄ induces an apical ATP release through the pannexin (Panx1) channel activating a purinoreceptor pathway. Activation of P2Y₁₁ receptors stimulates chloride secretion out of the cell by calcium activated chloride channels (CaCC) and inhibition of sodium absorption by amiloride sensitive epithelial sodium channels (ENaC) which result in a restored ASL height in CF bronchial epithelial cells. The calcium signal induced by P2Y₁₁ activation also stimulates epithelial repair and tight junction formation. Taken together, the physiological effects induced by LXA₄ have the potential to delay the invasion of bronchial epithelial cells by bacteria (green and orange structures).

thrombin resulted in a strong ATP release response that was inhibited by the nonselective blockers of pannexin channels suggesting that ATP release from thrombin-stimulated lung epithelial cells occurs through pannexin channels [87]. A study by Ransford et al. 2009 showed ATP release induced by hypotonic shock of human bronchial epithelial cells was inhibited after silencing pannexin-1 (Panx1) via shRNA [88]. The large pores of Panx1 (the most studied pannexin channel) are permeable to ions, second messengers, and neurotransmitters such as ATP, IP₃, and amino acids. Panx1 is also implicated in secretion of arachidonic acid and its metabolites and it is now widely regarded that Panx1 membrane channels are also involved in the extracellular mode of wave propagation. Panx1 channels open in response to mechanical stress or other stimuli such as depolarization and release ATP to the extracellular medium. ATP binding to purinergic receptors triggers an increase of cytoplasmic Ca²⁺ via the IP₃ pathway. The Ca²⁺ increase is not restricted to the same cell but also includes cells within diffusion distance for the released ATP also stimulating cells that are coupled to the stimulated cell by gap junction channels permitting the flux of IP₃.

The increase in Ca²⁺ can activate Panx1 channels and subsequent release of ATP provides a new source for extracellular ATP to reach more distant cells [86]. The application of micromolar concentrations of Ca²⁺ to the cytoplasmic side of Panx1 channels in excised membrane patches activated the channels at negative membrane potentials where the channels are normally closed [86].

4.3. Lipoxin A₄ Increases the Airway Surface Liquid Height via P2Y₁₁ Activation. The mechanism by which LXA₄ stimulates Ca²⁺-activated Cl⁻ secretion and ASL height increase has been elucidated. Higgins et al. reported that LXA₄ induces an apical ATP release from non-CF and CF airway epithelial cell lines and CF primary cultures. This ATP release induced by LXA₄ is completely inhibited by antagonists of the FPR2 receptor and Panx1 channels suggesting a major role of Panx1 in this effect. Furthermore, LXA₄ induces an increase in intracellular cAMP and calcium, which are abolished by the selective inhibition of the P2RY₁₁ purinoreceptor. Panx1 and ATP hydrolysis inhibition and P2RY₁₁ purinoreceptor knockdown all abolish the increase of ASL height induced by LXA₄. Inhibition of the A₂b adenosine receptor does not affect the ASL height increase induced by LXA₄, whereas the PKA inhibitor partially inhibits this response. Taken together this report provides evidence for a novel role of LXA₄ in stimulating apical ATP secretion via Panx1 channel and subsequent P2RY₁₁ purinoreceptor activation in airway epithelial cells leading to an ASL height increase (Figure 3).

5. Epithelial Repair in CF Airway
5.1. Altered Epithelial Repair in CF. In CF, recurrent infections and inflammatory insults result in damage to the airways and trigger the repair process [89]. Epithelial repair initially involves cell migration and cell proliferation to repopulate the injured area [90–92]. This process is then followed by differentiation of the epithelium [93]. Recent research suggests that epithelial repair as well as differentiation of the CF airway epithelium is downregulated or delayed [94–98]. More specifically, cell migration and proliferation both appear to be reduced during repair of CF bronchial
epithelial cells compared to non-CF cells [99]. This delay in repair of the CF epithelium renders the lung more susceptible to ongoing bacterial infection and thus may trigger more epithelial damage [100].

5.2. Lipoxin A₄ Regulates Airway Epithelial Integrity in CF Airway Epithelium. The lipid mediator LXA₄ triggers epithelial cell migration and proliferation and thus plays a role in repair of epithelia including bronchial epithelium from patients with CF [22, 99, 101–104]. The effects of LXA₄ in stimulating cell proliferation, cell migration, and wound repair are mediated by the apical ATP release and P2Y11 activation [105]. Stimulation of P2Y11 purinoceptors induces calcium release and ERK phosphorylation, both of which play a key role in initiating cell proliferation and migration [106–113]. Furthermore, consistent with the role of potassium channels in two key processes of repair, migration, and proliferation in numerous cell types, the responses to LXA₄ on the repair process are mediated by the downstream activation of Kᵥ ATP potassium channels [96, 97, 99, 114–117]. Additionally, LXA₄ enhances airway epithelial tight junction formation which is a major factor of epithelial barrier integrity. LXA₄ stimulates ZO-1, claudin-1, and occludin expression and trafficking at the apical membrane resulting in enhanced transepithelial electrical resistance in human airway epithelia [118] (Figure 2). Taken together, these effects of LXA₄ on airway epithelial structure suggest the abnormal levels of LXA₄ in CF airways may account for the reduced capacity for epithelial repair in CF.

6. Treatments of CF Airway Disease

6.1. Current Treatments and Opportunities. There is currently no treatment available that fully corrects the biochemical abnormality in CF and leads to a cessation of the typical pathobiology seen in the condition. Therapies to date have been centred on slowing the decline in pulmonary function over time to prolong survival. Medication is predominantly used to optimise nutrition (pancreatic enzymes, fat soluble vitamin supplementation), treat infection (oral, inhaled, and intravenous antibiotics), and facilitate effective mucociliary clearance (DNase, hypertonic saline). Several anti-inflammatory approaches have been examined in CF; however, the ideal anti-inflammatory drug is not yet available [119]. A recent systematic review of the risks and benefits of inhaled corticosteroids in CF, examining evidence from 13 trials, concluded that there is insufficient evidence to establish whether they are beneficial in CF while it is established that ICS use can have adverse effects [120]. A systematic review of the efficacy of nonsteroidal anti-inflammatory drugs in CF concluded that treatment with high-dose ibuprofen was associated with a significantly lower annual rate of decline in lung function (especially in children); however, the adoption of ibuprofen into therapy has not been universally accepted [121]. Correcting the imbalance in fatty acid metabolism described in CF by supplementation of Docosahexaenoic Acid may be helpful, and efforts are ongoing to evaluate the potential therapeutic benefit [122].

Two promising avenues of therapy have recently emerged: small molecule correctors and gene therapy. The flagship small molecule corrector has been Ivacaftor (VX-770). This compound facilitates gating of defective CFTR where the cause of CFTR dysfunction is a gating mutation—predominantlyG551D. This has been remarkably clinically successful but can be taken by only approximately 5% of patients worldwide [123, 124]. The manufacturers of Ivacaftor, Vertex Pharmaceuticals, are currently developing correctors for the commonest mutation Phe508del. Phase 2 trials of this compound have been shown to lead to positive changes in CFTR function, but not to the same degree as VX-770 [125]. Gene therapy was considered an obvious target for disease modifying treatment after the discovery of the CFTR gene; however initial attempts at this approach were unsuccessful, prompting a comprehensive review of the process of selection of endpoints, vectors, and delivery modes. A consortium in the UK has developed a comprehensive approach in this regard and will report shortly on multidose trials of gene therapy in individuals with CF [126]. A treatment approach capable of effectively preventing lung damage and decline in pulmonary function is currently absent despite the obvious hope relating to new developments.

For now, we continue to search for new and effective therapies to slow or prevent the decline in pulmonary function in CF.

6.2. Therapeutic Potential for LXA₄ in the Treatment of CF Airway Disease. A variety of airway clearance therapies have been developed for patients with CF [127, 128]. Thus identification of agents, particularly endogenous biologicals that stimulate non-CFTR CF secretory pathways and promote ASL height recovery while providing anti-inflammatory effects are likely to be of therapeutic benefit in improving mucociliary clearance in patients with CF. The effect of LXA₄ inhalation has been evaluated in a pilot study of eight asthmatic and healthy adult subjects. The challenge was tolerated, had no adverse effect on pulse or blood pressure, and demonstrated favourable effects on specific airway conductance [129].

In conclusion, the discovery of the multiple impacts of LXA₄ in restoring bronchial epithelium ion transport, in enhancing ASL height, in restoring epithelial barrier function, and in reducing inflammation might provide significant advance in treatment of the CF airway disease (Figure 3).

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

[1] B. D. Levy, C. B. Clish, B. Schmidt, K. Gronert, and C. N. Serhan, “Lipid mediator class switching during acute inflammation: signals in resolution,” Nature Immunology, vol. 2, no. 7, pp. 612–619, 2001.

[2] F. C. Ringholz, P. J. Buchanan, D. T. Clarke et al., “Reduced 15-lipoxygenase 2 and lipoxin A4/leukotriene B4 ratio in children with cystic fibrosis,” The European Respiratory Journal, vol. 44, no. 2, pp. 394–404, 2014.
[3] J. Z. Haeggström and C. D. Funk, “Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease,” *Chemical Reviews*, vol. 111, no. 10, pp. 5866–5896, 2011.

[4] N. Mukaida, S. Okamoto, Y. Ishikawa, and K. Matsushima, “Molecular mechanism of interleukin-8 gene expression,” *Journal of Leukocyte Biology*, vol. 56, no. 5, pp. 554–558, 1994.

[5] C. N. Serhan, S. Yacoubian, and R. Yang, “Anti-inflammatory and proresolving lipid mediators,” *Annual Review of Pathology*, vol. 3, pp. 279–312, 2008.

[6] I. M. Fierro and C. N. Serhan, “Mechanisms in anti-inflammatory and resolution: the role of lipoxins and aspirin-triggered lipoxins,” *Brazilian Journal of Medical and Biological Research*, vol. 34, no. 4, pp. 555–566, 2001.

[7] C. Chavis, I. Vachier, P. Chanez, J. Bousquet, and P. Godard, “F(5S), 15(S)-dihydroxyecosatetraenoic acid and lipoxin generation in human polymorphonuclear cells: dual specificity of 5-lipoxygenase towards endogenous and exogenous precursors,” *Journal of Experimental Medicine*, vol. 183, no. 4, pp. 1633–1643, 1996.

[8] C. N. Serhan, U. Hirsch, J. Palmblad, and B. Samuelsson, “Formation of lipoxin A by granulocytes from eosinophilic donors,” *FEBS Letters*, vol. 217, no. 2, pp. 242–246, 1987.

[9] B. D. Levy, S. Bertram, H. H. Tai et al., “Argon-induced lipoxin A4 generation: detection by a novel lipoxin A4-ELISA,” *Lipids*, vol. 28, no. 12, pp. 1047–1053, 1993.

[10] C. Chavis, I. Vachier, P. Chanez, J. Bousquet, and P. Godard, “Lipoxin formation during human neutrophil-platelet interactions: evidence for the transformation of leukotriene A4 by platelet 12-lipoxygenase in vitro,” *Journal of Clinical Investigation*, vol. 85, no. 3, pp. 772–780, 1990.

[11] J. Claria, M. H. Lee, and C. N. Serhan, “Aspirin-triggered lipoxins (15-epi-LX) are generated by the human lung adenocarcinoma cell line (A549)-neutrophil interactions and are potent inhibitors of cell proliferation,” *Molecular Medicine*, vol. 2, no. 5, pp. 583–596, 1996.

[12] “Special issue: the lipoxins and the aspirin-triggered lipoxins,” *Prostaglandins, Leukotrienes & Essential Fatty Acids*, vol. 73, no. 3-4, pp. 139–201, 2005.

[13] B. D. Levy, M. Romano, H. A. Chapman, J. J. Reilly, J. Drazen, and C. N. Serhan, “Human alveolar macrophages have 15-lipoxygenase and generate 15(S)-hydroxy-5,8,11-cis-13-trans-eicosatetraenoic acid and lipoxins,” *Journal of Clinical Investigation*, vol. 92, no. 3, pp. 1572–1579, 1993.

[14] I. Vachier, P. Chanez, C. Bonnans, P. Godard, J. Bousquet, and C. Chavis, “Endogenous anti-inflammatory mediators from arachidionate in human neutrophils,” *Biochemical and Biophysical Research Communications*, vol. 290, no. 1, pp. 219–224, 2002.

[15] N. Chiang, M. Arita, and C. N. Serhan, “Anti-inflammatory circuitry: lipoxin, aspirin-triggered lipoxins and their receptor ALX,” *Prostaglandins, Leukotrienes & Essential Fatty Acids*, vol. 73, no. 3-4, pp. 163–177, 2005.

[16] N. Chiang, S. Hurwitz, P. M. Ridker, and C. N. Serhan, “Aspirin has a gender-dependent impact on antiinflammatory 15-epi-lipoxin A4 formation: a randomized human trial,” *Atherosclerosis, Thrombosis, and Vascular Biology*, vol. 26, no. 2, pp. e14–e17, 2006.

[17] G. Ying, P. Iriharren, Y. Zhou et al., “Humanin, a newly identified neuroprotective factor, uses the G protein-coupled formyl peptide receptor-like-1 as a functional receptor,” *Journal of Immunology*, vol. 172, no. 11, pp. 7078–7085, 2004.

[18] F. Cattaneo, M. Parisi, and R. Ammendola, “Distinct signaling cascades elicited by different formyl peptide receptor 2 (FPR2) agonists,” *International Journal of Molecular Sciences*, vol. 14, no. 4, pp. 7193–7230, 2013.

[19] R. D. Ye, F. Boulay, M. W. Ji et al., “International union of basic and clinical pharmacology. Lxxiii. Nomenclature for the formyl peptide receptor (fpr) family,” *Pharmacological Reviews*, vol. 61, no. 2, pp. 119–161, 2009.

[20] N. Chiang, C. N. Serhan, S.-E. Dahlén et al., “The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo,” *Pharmacological Reviews*, vol. 58, no. 3, pp. 463–487, 2006.

[21] C. N. Serhan, “Lipoxins and aspirin-triggered 15-epi-lipoxin biosynthesis: an update and role in anti-inflammatory and resolution,” *Prostaglandins and Other Lipid Mediators*, vol. 68-69, pp. 433–455, 2002.

[22] C. Bonnans, K. Fukunaga, M. A. Levy, and B. D. Levy, “Lipoxin A4 regulates bronchial epithelial cell responses to acid injury,” *The American Journal of Pathology*, vol. 168, no. 4, pp. 1064–1072, 2006.

[23] S. P. Colgan, C. N. Serhan, C. A. Parkos, C. Delp-Archer, and J. L. Madara, “Lipoxin A4 modulates transmigration of human neutrophils across intestinal epithelial monolayers,” *Journal of Clinical Investigation*, vol. 92, no. 1, pp. 75–82, 1993.

[24] T. Takano, C. B. Clish, K. Gronert, N. Petasis, and C. N. Serhan, “Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogues,” *The Journal of Clinical Investigation*, vol. 101, no. 4, pp. 819–826, 1998.

[25] L. Józef, C. Zhouki, N. A. Petasis, C. N. Serhan, and J. G. Filep, “Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-κB and AP-1 activation, and IL-8 gene expression in human leukocytes,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 99, no. 20, pp. 13266–13271, 2002.

[26] C. Bonnans and B. D. Levy, “Lipid mediators as agonists for the resolution of acute lung inflammation and injury,” *The American Journal of Respiratory Cell and Molecular Biology*, vol. 36, no. 2, pp. 201–205, 2007.

[27] A. T. Gewirtz, B. McCormick, A. S. Neish et al., “Pathogen-induced chemokine secretion for model intestinal epithelium is inhibited by lipoxin A4 analogs,” *Journal of Clinical Investigation*, vol. 101, no. 9, pp. 1860–1869, 1998.

[28] V. Verriere, Y. Grumbach, R. Chiron, and V. Urbach, “LXA4 effect on intracellular Ca2+,” *Cl− secretion and IL-8 production in normal and CF airway epithelium,” *Revue des Maladies Respiratoires*, vol. 23, no. 5, p. 574, 2006.

[29] C. L. Karp, L. M. Flick, K. W. Park et al., “Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway,” *Nature Immunology*, vol. 5, no. 4, pp. 388–392, 2004.

[30] C. Godson, S. Mitchell, K. Harvey, N. A. Petasis, N. Hogg, and H. R. Brady, “Cutting edge: lipoxins rapidly stimulate non-phlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages,” *Journal of Immunology*, vol. 164, no. 4, pp. 1663–1667, 2000.

[31] B. McMahon, S. Mitchell, H. R. Brady, and C. Godson, “Lipoxins: revelations on resolution,” *Trends in Pharmacological Sciences*, vol. 22, no. 8, pp. 391–395, 2001.

[32] D. H. Andersen, “Cystic fibrosis of the pancreas and its relation to celiac disease: a clinical and pathologic study,” *Archives of Pediatrics & Adolescent Medicine*, vol. 56, no. 2, pp. 344–399, 1938.

[33] L.-C. Tsai, M. Buchwald, D. Barker et al., “Cystic fibrosis locus defined by a genetically linked polymorphic DNA marker,” *Science*, vol. 230, no. 4729, pp. 1054–1057, 1985.
A. L. Manson, A. E. O. Trezise, L. J. MacVinish et al., "Localization of cystic fibrosis locus to human chromosome 7cen-q22," Nature, vol. 318, no. 6044, pp. 384–385, 1985.

R. White, S. Woodward, M. Leppert et al., "A closely linked genetic marker for cystic fibrosis," Nature, vol. 318, no. 6044, pp. 382–384, 1985.

J. R. Riordan, J. M. Rommens, B.-S. Kerem et al., "Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA," Science, vol. 245, no. 4922, pp. 1066–1073, 1989.

A. Bush, E. Alton, J. C. Davies, U. Griesenbach, and A. Jaffe, eds., Cystic Fibrosis in the 21st Century: Progress in Research, Karger, Basel, Switzerland, 2006.

M. Wilschanski, J. Zielenkszi, D. Markiewicz et al., "Correlation of sweat chloride concentration with classes of the cystic fibrosis transmembrane conductance regulator gene mutations," The Journal of Pediatrics, vol. 127, no. 5, pp. 705–710, 1995.

M. J. Welsh and A. E. Smith, "Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis," Cell, vol. 73, no. 7, pp. 1251–1254, 1993.

J. F. Engelhardt, J. R. Yankaskas, S. A. Ernst et al., "Submucosal glands are the predominant site of CFTR expression in the human bronchus," Nature Genetics, vol. 2, no. 3, pp. 240–248, 1992.

A. E. O. Trezise and M. Buchwald, "In vivo cell-specific expression of the cystic fibrosis transmembrane conductance regulator," Nature, vol. 353, no. 6343, pp. 434–437, 1991.

N. Kartner, O. Augustinas, T. J. Jensen, A. L. Naismith, and J. R. Riordan, "Mislocalization of ΔF508 CFTR in cystic fibrosis sweat gland," Nature Genetics, vol. 1, no. 5, pp. 321–327, 1992.

A. E. Trezise, J. A. Chambers, C. J. Wardle, S. Gould, and A. Harris, "Expression of the cystic fibrosis gene in human foetal tissues," Human Molecular Genetics, vol. 2, no. 3, pp. 213–218, 1993.

A. L. Manson, A. E. O. Trezise, L. J. MacVinish et al., "Complementation of null CF mice with a human CFTR YAC transgene," The EMBO Journal, vol. 16, no. 14, pp. 4238–4249, 1997.

T. F. Boat and P. W. Cheng, "Epithelial cell dysfunction in cystic fibrosis: implications for airways disease," Acta Paediatrica Scandinavica, Supplement, vol. 363, pp. 25–29, 1989.

J. E. Mickle, M. Macek Jr., S. B. Fulmer-Smentek et al., "A mutation in the cystic fibrosis transmembrane conductance regulator gene associated with elevated sweat chloride concentrations in the absence of cystic fibrosis," Human Molecular Genetics, vol. 7, no. 4, pp. 729–735, 1998.

R. G. Painter, V. G. Valentine, N. A. Lanson Jr. et al., "CFTR expression in human neutrophils and the phagolysosomal chlorination defect in cystic fibrosis," Biochemistry, vol. 45, no. 34, pp. 10260–10269, 2006.

R. G. Painter, R. W. Bonvillain, V. G. Valentine et al., "The role of chloride anion and CFTR in killing of Pseudomonas aeruginosa by normal and CF neutrophils," Journal of Leukocyte Biology, vol. 83, no. 6, pp. 1345–1353, 2008.

A. Di, M. E. Brown, L. V. Deriy et al., "CFTR regulates phagosome acidification in macrophages and alters bactericidal activity," Nature Cell Biology, vol. 8, no. 9, pp. 933–944, 2006.

T. L. Bonfield, C. A. Hodges, C. U. Cotton, and M. L. Drumm, "Absence of the cystic fibrosis transmembrane regulator (CFTR) from myeloid-derived cells slows resolution of inflammation and infection," Journal of Leukocyte Biology, vol. 92, no. 5, pp. 1111–1122, 2012.

A. M. van Heeckeren and M. D. Schluchter, "Murine models of chronic Pseudomonas aeruginosa lung infection," Laboratory Animals, vol. 36, no. 3, pp. 291–312, 2002.

C. Bonnans, I. Vacher, C. Chavis, P. Godard, J. Bousquet, and P. Chanez, "Lipoxins are potential endogenous antiinflammatory mediators in asthma," American Journal of Respiratory and Critical Care Medicine, vol. 165, no. 11, pp. 1531–1535, 2002.

A. Planagumà, S. Kuzani, G. Marigowda et al., "Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma," The American Journal of Respiratory and Critical Care Medicine, vol. 178, no. 6, pp. 574–582, 2008.

L. Balode, G. Strazda, N. Jurka et al., "Lipoxygenase-derived arachidonic acid metabolites in chronic obstructive pulmonary disease," Medicina, vol. 48, no. 6, pp. 292–298, 2012.

R. Chiron, Y. Y. Grumbach, N. V. T. Quynh, V. Verriere, and V. Urbach, "Lipoxin A4 and interleukin-8 levels in cystic fibrosis sputum after antibiotics," Journal of Cystic Fibrosis, vol. 7, no. 6, pp. 463–468, 2008.

V. Starosta, F. Ratjen, E. Rietschel, K. Paul, and M. Griese, "Anti-inflammatory cytokines in cystic fibrosis lung disease," European Respiratory Journal, vol. 28, no. 3, pp. 581–587, 2006.

T. Carlo, H. Kalwa, and B. D. Levy, "15-Epi-lipoxin A4 inhibits human neutrophil superoxide anion generation by regulating polyisoprenyl diphosphate phosphatase 1," The FASEB Journal, vol. 27, no. 7, pp. 2733–2741, 2013.

D. Mattoscio, V. Evangelista, R. De Cristofaro et al., "Cystic fibrosis transmembrane conductance regulator (CFTR) expression in human platelets: impact on mediators and mechanisms of the inflammatory response," The FASEB Journal, vol. 24, no. 10, pp. 3970–3980, 2010.

R. C. Boucher, "Airway surface dehydration in cystic fibrosis: pathogenesis and therapy," Annual Review of Medicine, vol. 58, pp. 157–170, 2007.

H. Matsui, C. W. Davis, R. Tarran, and R. C. Boucher, "Osmotic water permeabilities of cultured, well-differentiated normal and cystic fibrosis airway epithelia," Journal of Clinical Investigation, vol. 105, no. 10, pp. 1419–1427, 2000.

K. Kunzelmann, G. L. Kiser, R. Schreibe, and J. R. Riordan, "Inhibition of epithelial Na+ currents by intracellular domains of the cystic fibrosis transmembrane conductance regulator, FEBS Letters, vol. 400, no. 3, pp. 341–344, 1997.

M. J. Stutts, C. M. Canessa, J. C. Olsen et al., "CFTR as a CAMP-dependent regulator of sodium channels," Science, vol. 269, no. 5225, pp. 847–850, 1995.

P. B. Davis, M. Drumm, and M. W. Konstan, "Cystic fibrosis," American Journal of Respiratory and Critical Care Medicine, vol. 154, no. 5, pp. 1229–1256, 1996.

D. Wörliitzsch, R. Tarran, M. Ulrich et al., "Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients," The Journal of Clinical Investigation, vol. 109, no. 3, pp. 317–325, 2002.

R. C. Boucher, M. J. Stutts, M. R. Knowles, L. Cantley, and J. T. Gatzy, "Na+ transport in cystic fibrosis respiratory epithelia. Abnormal basal rate and response to adenylate cyclase activation," Journal of Clinical Investigation, vol. 78, no. 5, pp. 1245–1252, 1986.

R. C. Boucher, "Regulation of airway surface liquid volume by human airway epithelia," Pflügers Archiv, vol. 445, no. 4, pp. 495–498, 2003.

F. Antigny, C. Norez, F. Becq, and C. Vandebrouck, "CFTR and Ca2+ signaling in cystic fibrosis," Frontiers in Pharmacology, vol. 2, no. 67, 2011.
[68] N. Pillarisetti, B. Linnane, and S. Ranganathan, “Early bronchiectasis in cystic fibrosis detected by surveillance CT,” Respirology, vol. 15, no. 6, pp. 1009–1011, 2010.

[69] N. Pillarisetti, E. Williamson, B. Linnane et al., “Infection, inflammation, and lung function decline in infants with cystic fibrosis,” The American Journal of Respiratory and Critical Care Medicine, vol. 184, no. 1, pp. 75–81, 2011.

[70] F. Ratjen, “What's new in CF airway inflammation: an update,” Paediatric Respiratory Reviews, vol. 7, supplement 1, pp. S70–S72, 2006.

[71] C. Bonnans, P. Chanez, H. Meziane, P. Godard, J. Bousquet, and I. Vacher, “Glucocorticoid receptor-binding characteristics in severe asthma,” European Respiratory Journal, vol. 21, no. 6, pp. 985–988, 2003.

[72] V. Verrière, G. Higgins, M. Al-Alawi et al., “Lipoxin a4 stimulates calcium-activated chloride currents and increases airway surface liquid height in normal and cystic fibrosis airway epithelia,” PLoS ONE, vol. 7, no. 5, Article ID e37746, 2012.

[73] M. Al-Alawi, P. Buchanan, V. Verrière et al., “Physiological levels of lipoxin a4 inhibit enac and restore airway surface liquid height in cystic fibrosis bronchial epithelium,” Physiological Reports, vol. 2, no. 8, 2014.

[74] S. J. Mason, A. M. Paradiso, and R. C. Boucher, “Regulation of transepithelial ion transport and intracellular calcium by extracellular ATP in human normal and cystic fibrosis airway epithelium,” British Journal of Pharmacology, vol. 103, no. 3, pp. 1649–1656, 1991.

[75] M. R. Knowles, L. L. Clarke, and R. C. Boucher, “Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis,” The New England Journal of Medicine, vol. 325, no. 8, pp. 533–538, 1996.

[76] E. R. Lazarowski, R. Tarann, B. R. Grubb, C. A. van Heusden, S. Okada, and R. C. Boucher, “Nucleotide release provides a mechanism for airway surface liquid homeostasis,” The Journal of Biological Chemistry, vol. 279, no. 35, pp. 36855–36864, 2004.

[77] B. M. Rollins, M. Burn, R. D. Coakley et al., “AB adenosine receptors regulate the mucus clearance component of the lung’s innate defense system,” The American Journal of Respiratory Cell and Molecular Biology, vol. 39, no. 2, pp. 190–197, 2008.

[78] M. Mall, A. Wissner, T. Gonska et al., “Inhibition of amiloride-sensitive epithelial Na⁺ absorption by extracellular nucleotides in human normal and cystic fibrosis airways,” The American Journal of Respiratory and Critical Care Biology, vol. 23, no. 6, pp. 755–761, 2000.

[79] E. R. Lazarowski and R. C. Boucher, “Purinergic receptors in airway epithelia,” Current Opinion in Pharmacology, vol. 9, no. 3, pp. 262–267, 2009.

[80] I. M. Lorenzo, W. Liedtke, M. J. Sanderson, and M. A. Valverde, “TRPV4 channel participates in receptor-operated calcium entry and ciliary beat frequency regulation in mouse airway epithelial cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 34, pp. 12611–12616, 2008.

[81] D. Communi, S. Piroton, M. Parmentier, and J.-M. Boeynaems, “Cloning and functional expression of a human uridine nucleotide receptor,” Journal of Biological Chemistry, vol. 270, no. 52, pp. 30849–30852, 1995.

[82] K. R. Vaughan, L. Stokes, L. R. Prince et al., “Inhibition of neutrophil apoptosis by ATP is mediated by the P2Y11 receptor,” The Journal of Immunology, vol. 179, no. 12, pp. 8544–8553, 2007.

[83] Z. Xiao, M. Yang, Q. Lv et al., “P2Y11 impairs cell proliferation by induction of cell cycle arrest and sensitizes endothelial cells to cisplatin-induced cell death,” Journal of Cellular Biochemistry, vol. 112, no. 9, pp. 2257–2265, 2011.

[84] T. D. Nguyen, S. Meichle, U. S. Kim, T. Wong, and M. W. Moody, “P2Y11, a purinergic receptor acting via cAMP, mediates secretion by pancreatic duct epithelial cells,” American Journal of Physiology: Gastrointestinal and Liver Physiology, vol. 280, no. 5, pp. G795–G804, 2001.

[85] R. S. Sprague, M. L. Ellsworth, A. H. Stephenson, and A. J. Lonigro, “ATP: the red blood cell link to NO and local control of the pulmonary circulation,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 271, no. 6, part 2, pp. H2717–H2722, 1996.

[86] G. Dahl and S. Locovei, “Pannexin: to gap or not to gap, is that a question?” IUBMB Life, vol. 58, no. 7, pp. 409–419, 2006.

[87] L. Seminario-Vidal, S. Kreda, L. Jones et al., “Thrombin promotes release of ATP from lung epithelial cells through coordinated activation of Rho- and Ca²⁺-dependent signaling pathways,” Journal of Biological Chemistry, vol. 284, no. 31, pp. 20638–20648, 2009.

[88] G. A. Ransford, N. Fregien, F. Qi, G. Dahl, G. E. Conner, and M. Salathe, “Pannexin 1 contributes to ATP release in airway epithelia,” The American Journal of Respiratory Cell and Molecular Biology, vol. 41, no. 5, pp. 525–534, 2009.

[89] N. Regamey, P. K. Jeffery, E. W. Alton, A. Bush, and J. C. Davies, “Airway remodelling and its relationship to inflammation in cystic fibrosis,” Thorax, vol. 66, no. 7, pp. 624–629, 2011.

[90] B. R. Stripp and S. D. Reynolds, “Maintenance and repair of the bronchial epithelium,” Proceedings of the American Thoracic Society, vol. 5, no. 3, pp. 328–333, 2008.

[91] J. M. Zahm, M. Chevillard, and E. Puchelle, “Wound repair of human surface respiratory epithelium,” The American Journal of Respiratory Cell and Molecular Biology, vol. 5, no. 3, pp. 242–248, 1991.

[92] J. M. Zahm, H. Kaplan, A. L. Hérard et al., “Cell migration and proliferation during the in vitro wound repair of the respiratory epithelium,” Cell Motility and the Cytoskeleton, vol. 37, no. 1, pp. 33–43, 1997.

[93] J. S. Erjefalt, I. Erjefalt, S. Sundler, and C. G. A. Persson, “In vivo restitution of airway epithelium,” Cell and Tissue Research, vol. 281, no. 2, pp. 305–316, 1995.

[94] N. T. N. Trinh, O. Bardou, A. Privé et al., “Improvement of defective cystic fibrosis airway epithelial wound repair after CFTR rescue,” European Respiratory Journal, vol. 40, no. 6, pp. 1390–1400, 2012.

[95] E. Maillé, N. T. N. Trinh, A. Privé et al., “Regulation of normal and cystic fibrosis airway epithelial repair processes by TNF-α after injury,” American Journal of Physiology Lung Cellular and Molecular Physiology, vol. 301, no. 6, pp. L945–L955, 2011.

[96] N. T. N. Trinh, A. Privé, E. Maillé, J. Noël, and E. Brochiero, “EGF and KvLQT1K+ channel activity control normal and cystic fibrosis bronchial epithelia repair,” American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 295, no. 5, pp. L866–L880, 2008.
K. Gronert, N. Maheshwari, N. Khan, I. R. Hassan, M. Dunn, P. Roger, E. Puchelle, O. Bajolet-Laudinat et al., “Fibronectin C. L. Sheppard, R. C. Lantz, J. L. Burgess, and S. Boitano, J. Y. and F.-S. Yu, “Erk1/2 mediate wounding and g-protein- mediated K+ channel activation results in cystic fibrosis airway epithelial repair,” The American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 305, no. 2, pp. L193–L201, 2013.

P. Roger, E. Puchelle, O. Bajolet-Laudinat et al., “Fibronectin and α5β1 integrin mediate binding of Pseudomonas aeruginosa to repairing airway epithelium,” European Respiratory Journal, vol. 13, no. 6, pp. 1301–1309, 1999.

K. Gronert, “Fibronectin in the eye and their role in wound healing,” Prostaglandins, Leukotrienes & Essential Fatty Acids, vol. 73, no. 3–4, pp. 221–229, 2005.

S. Kchenegowda, N. G. Bazan, and H. E. P. Bazan, “EGF stimulates lipoxin A4 synthesis and modulates repair in corneal epithelial cells through ERK and p38 activation,” Investigative Ophthalmology and Visual Science, vol. 52, no. 5, pp. 2240–2249, 2011.

T. B. Wang, K. M. Hu, K. J. Seamon, V. Mani, Y. Chen, and K. Gronert, “Estrogen negatively regulates epithelial wound healing and protective lipid mediator circuits in the cornea,” FASEB Journal, vol. 26, no. 4, pp. 1506–1516, 2012.

K. Gronert, N. Maheshwari, N. Khan, I. R. Hassan, M. Dunn, and M. L. Schwartzman, “A role for the mouse 12/15-lipoxygenase pathway in promoting epithelial wound healing and host defense,” Journal of Biological Chemistry, vol. 280, no. 15, pp. 15267–15278, 2005.

G. Higgins, P. Buchanan, M. Perriere et al., “Activation of P2RY11 and ATP release by lipoxin A4 restores the airway surface liquid layer and epithelial repair in cystic fibrosis,” American Journal of Respiratory Cell and Molecular Biology, vol. 51, no. 2, pp. 178–190, 2014.

I. M. Balfour-Lynn and K. Welch, “Inhaled corticosteroids for cystic fibrosis airways disease,” Current Opinion in Pulmonary Medicine, vol. 13, no. 6, pp. 522–528, 2007.

I. M. Balfour-Lynn and K. Welch, “Inhaled corticosteroids for cystic fibrosis,” Cochrane Database of Systematic Reviews, vol. II, 2012.

L. C. Lands and S. Stanojevic, “Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis,” The Cochrane Database of Systematic Reviews, vol. 6, Article ID CD001505, 2013.

S. van Biervliet, J. P. van Biervliet, E. Robberecht, and A. Christophe, “Docosahexaenoic acid trials in cystic fibrosis: a review of the rationale behind the clinical trials,” Journal of Cystic Fibrosis, vol. 4, no. 1, pp. 27–34, 2005.

F. J. Accurso, S. M. Rowe, J. P. Clancy et al., “Effect of VX-770 in persons with cystic fibrosis and the G551D mutation,” The New England Journal of Medicine, vol. 363, no. 21, pp. 1991–2003, 2010.

B. W. Ramsey, J. Davies, N. G. McElvaney et al., “A CFTR potentiator in patients with cystic fibrosis and the G551D mutation,” The New England Journal of Medicine, vol. 365, no. 18, pp. 1663–1672, 2011.

J. P. Clancy, L. Dupont, M. W. Konstan et al., “Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection,” Thorax, vol. 68, no. 9, pp. 818–825, 2013.

D. K. Armstrong, S. Cunningham, J. C. Davies, and E. W. F. W. van Biervliet, “Inhaled corticosteroids for cystic fibrosis airways disease,” Review of Respiratory Disease, vol. 145, no. 6, pp. 1281–1284, 1992.